Advanced Biomed Reports $2.56 Million Net Loss, Increases Total Assets to $8.29 Million

Advanced Biomed Inc. has reported its financial results for the nine-month period ending March 31, 2025, revealing a net loss of $2.56 million, a 30% increase from the $1.97 million loss recorded in the same period the previous year. The company's total operating expenses for the nine-month period were approximately $1.81 million, slightly down from $1.84 million in the prior year. The increase in net loss is attributed to a significant rise in other expenses, which surged to $764,266 from $156,017, primarily due to foreign exchange losses.

In terms of financial position, Advanced Biomed's total assets increased to $8.29 million as of March 31, 2025, compared to $4.46 million at the end of June 2024. This growth was driven by a substantial rise in current assets, which reached $7.73 million, up from $3.05 million. The company’s cash reserves also saw a notable increase, ending the period at $5.18 million, compared to $2.61 million in the previous fiscal year. The increase in cash was largely due to the successful completion of an initial public offering (IPO) in March 2025, which raised approximately $6.56 million.

Operationally, Advanced Biomed has made significant strides in its product development and market expansion efforts. The company has completed the research and development phase for several oncology-related products, including the A+Pre and AC-1000 devices, which are designed for cancer detection and treatment. The company is also in the process of registering additional products, including the A+LCGuard Lung Cancer Early Screening Kit, with clinical trials expected to commence by June 2025. Furthermore, Advanced Biomed is planning to expand its operations into North America and Europe, with site selection and personnel recruitment targeted for completion by the end of 2025.

The company’s workforce has also seen changes, with an increase in employee headcount as it prepares for its expansion and product launches. As of March 31, 2025, Advanced Biomed reported a total of 21,640,000 shares outstanding, reflecting the impact of a recent share issuance during the IPO. The company’s management has indicated that it will continue to seek additional funding sources to support its operations and product development, emphasizing the importance of securing financial backing to maintain its growth trajectory.

Looking ahead, Advanced Biomed anticipates ongoing losses as it continues to invest heavily in research and development and navigate the regulatory landscape for its products. The company has expressed confidence in its strategic direction and the potential for future revenue generation once its products receive the necessary regulatory approvals. However, management has acknowledged the inherent risks and uncertainties associated with product development and market entry, which could impact the company's financial performance in the near term.